TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17710152
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose of HBV vaccine
Study: 15567983
Drug: Lactobacillus casei
Normalized name: Lactobacillus Casei
DrugBank: Lactobacillus casei (DB16541)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus casei supplementation (750 mg daily containing 16 billion bacteria)
Study: 15567983
Drug: Standard quadruple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard quadruple therapy without Lactobacillus casei supplementation
Study: 28351393
Drug: Honey supplementation
Normalized name: Honey
DrugBank: Honey (DB14242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Honey supplementation (20 g/day for 12 weeks)
Study: 24365449
Drug: Rifaximin (550
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin (550 mg, twice daily)
Study: 22034767
Drug: Spinal manipulative
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal manipulative treatment
Study: 22034767
Drug: Other advocated
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other advocated therapies
Study: 16869815
Drug: Adefovir dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adefovir dipivoxil (ADV) 20 mg
Study: 16869815
Drug: Adefovir dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adefovir dipivoxil (ADV) 40 mg
Study: 16869815
Drug: Adefovir dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adefovir dipivoxil (ADV) multiple doses
Study: 9452157
Drug: Nitrate therapy
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate therapy (intravenous infusion or orally)
Study: 25136050
Drug: HPV4 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV4 vaccine
Study: 19821184
Drug: All patients
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients seeking treatment (n=416)
Study: 17209220
Drug: Vitamin and
Normalized name: Vitamin and Mineral Supplement
DrugBank: alpha-Tocopherol acetate (DB14003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin and multivitamin-mineral supplements
Study: 15902439
Drug: p-[(123)I]iodo-L-phenylalanine (IPA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: p-[(123)I]iodo-L-phenylalanine (IPA) SPECT
Study: 12054161
Drug: 150 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg/day of pamidronate
Study: 3516296
Drug: Terodiline 25
Normalized name: terodiline 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terodiline 25 mg bid
Study: 25472936
Drug: Heparin-bonded covered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-bonded covered stents (VIABAHN® Endoprosthesis)
Study: 18450596
Drug: Omega-3 LCPUFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 LCPUFA (350 mg DHA and 650 mg EPA)
Study: 14594184
Drug: Guided to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided to self-hypnotic relaxation
Study: 10949784
Drug: Meta-analysis of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meta-analysis of randomized, controlled trials of cancer therapy
Study: 21733143
Drug: Dietary advice
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary advice plus supplement
Study: 12757558
Drug: Donepezil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (5 mg/d for 4 weeks and 10 mg/d per clinician's judgment thereafter)
Study: 7955807
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg dihydroergotamine and 300 mg troxerutin three times a day
Study: 20684322
Drug: L-carnitine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (2 g/d) and vitamin E
Study: 18839655
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of human placenta purified extract (PE)
Study: 18839655
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of povidone iodine (PI)
Study: 14657817
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg levalbuterol
Study: 14657817
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg racemic albuterol
Study: 8783700
Drug: Oral nonabsorbable
Normalized name: COLLAGEN HEMOSTAT,ABSORBABLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nonabsorbable antibiotics for selective bowel decontamination (SBD)
Study: 8783700
Drug: Conventional prophylaxis
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional prophylaxis with systemic antibiotics (Control)
Study: 6421196
Drug: High nitrogen
Normalized name: Isosource High Nitrogen Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: High nitrogen intake (15 mg nitrogen per kcal REE, approximately 21 g/day)
Study: 6421196
Drug: Low nitrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low nitrogen intake (7.5 mg nitrogen per kcal REE, approximately 11 g/day)
Study: 27861670
Drug: Immediate implant
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate implant placement (test group)
Study: 27861670
Drug: Delayed implant
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed implant placement (control group)
Study: 19344527
Drug: High-dose rate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose rate (HDR) brachytherapy
Study: 17785979
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g chilli powder twice daily along with identical fiber and analgesics
Study: 17785979
Drug: Analgesics and
Normalized name: Analgesics and anesthetics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesics and fiber supplement alone
Study: 14628149
Drug: IR laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: IR laser treatment
Study: 8130021
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulphate (8 mmol loading dose over 5 minutes plus 65 mmol over 24 hours)
Study: 31212115
Drug: Insulin-requiring diabetics
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-requiring diabetics (IRD)
Study: 31212115
Drug: Non-insulin requiring
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-insulin requiring diabetics (NIRD)
Study: 28971636
Drug: Lornoxicam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam (20 mg)
Study: 17101314
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (880 mug, divided twice daily for 3 months)
Study: 11329400
Drug: Risperidone (2-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (2-6 mg/day, mean modal dose=4.8 mg/day)
Study: 11329400
Drug: Olanzapine (5-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (5-20 mg/day, mean modal dose=12.4 mg/day)
Study: 8970936
Drug: Thyroxine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroxine (8 microg per kilogram of birth weight) administered daily for six weeks
Study: 8970936
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered daily for six weeks
Study: 8215267
Drug: Cefonicid (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefonicid (2 g every 12 h)
Study: 2442991
Drug: Nadolol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol (mean dose 94 mg daily) plus class I antiarrhythmic agents (quinidine or procainamide)
Study: 2442991
Drug: Class I
Normalized name: HLA class I antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Class I antiarrhythmic agents alone
Study: 12171822
Drug: MDI/DED (metered-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDI/DED (metered-dose inhaler with delivery enhancement device)
Study: 12171822
Drug: Single bronchodilator
Normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single bronchodilator dose by wet nebulization
Study: 8583366
Drug: Intravenous milrinone
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous milrinone loading dose of 50 micrograms kg‐1 over 10 min followed by maintenance infusion of 0.45 micrograms kg‐1 min‐1 for moderate renal impairment (n = 10)
Study: 8583366
Drug: Intravenous milrinone
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous milrinone loading dose of 50 micrograms kg‐1 over 10 min followed by maintenance infusion of 0.35 micrograms kg‐1 min‐1 for severe renal impairment (n = 11)
Study: 8583366
Drug: Intravenous milrinone
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous milrinone (both groups)
Study: 2111933
Drug: Oral prophylactic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prophylactic penicillin
Study: 7030973
Drug: Pancuronium (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancuronium (0.05 and 0.1 mg/kg i.v.)
Study: 28062124
Drug: Text message
Approvals — FDA: no, EMA: no, PMDA: no
Description: Text message group (received two messages weekly for four consecutive weeks)
Study: 25726788
Drug: Adaptol (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adaptol (1000 mg daily for 30 days)
Study: 25726788
Drug: Noofen (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noofen (500 mg daily for 30 days)
Study: 23082447
Drug: Cabergoline 0.5
Normalized name: cabergoline 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline 0.5 mg weekly for 3 months
Study: 19572930
Drug: 1.25 mg/ml
Normalized name: menthol 1.25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg/ml ropivacaine
Study: 19572930
Drug: 1.25 mg/ml
Normalized name: menthol 1.25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg/ml ropivacaine with 0.2 mcg/kg/h fentanyl
Study: 19572930
Drug: 1.5 mg/ml
Normalized name: thymol 1.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/ml ropivacaine
Study: 19572930
Drug: 1.5 mg/ml
Normalized name: thymol 1.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/ml ropivacaine with 0.2 mcg/kg/h fentanyl
Study: 19572930
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (1.25 mg/ml ropivacaine)
Study: 8783388
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist D‐Trp6‐LHRH (Decapeptyl) 3.2 mg for 12 days
Study: 1902404
Drug: Intravenous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous heparin therapy (n = 99)
Study: 1902404
Drug: Aspirin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (300 mg/day) and dipyridamole (300 mg/day) (n = 103)
Study: 6353879
Drug: Ketanserin 20
Normalized name: ketanserin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin 20 mg t.i.d.
Study: 6353879
Drug: Ketanserin 40
Normalized name: ketanserin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin 40 mg t.i.d.
Study: 6353879
Drug: Ketanserin 60
Normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin 60 mg t.i.d.
Study: 6353879
Drug: Conventional drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional drugs (previous treatment)
Study: 30032443
Drug: Gynophilus® (Lcr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gynophilus® (Lcr regenerans®) immediate release capsules administered daily for 21 days
Study: 30032443
Drug: Gynophilus® slow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gynophilus® slow release muco-adhesive tablets administered every 3, 4, or 5 days for 21 days
Study: 30032443
Drug: Gynophilus® slow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gynophilus® slow release muco-adhesive tablets (administered every 3 or 4 days)
Study: 21948211
Drug: Restricted perioperative
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Restricted perioperative intravenous fluid regimen
Study: 21948211
Drug: Standard perioperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard perioperative intravenous fluid regimen
Study: 19584979
Drug: Ramipril 10
Normalized name: ramipril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril 10 mg/day for 12 weeks
Study: 12048365
Drug: Standard HIV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard HIV prevention services including access to free condoms, risk-reduction counseling, and STI therapy
Study: 10459399
Drug: Full (102-g)
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Full (102-g) 15-amino acid drink
Study: 10459399
Drug: Quarter-strength (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quarter-strength (25 g) 15-amino acid drink
Study: 8665996
Drug: Felodipine oral
Normalized name: felodipine Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine oral treatment for 8 weeks
Study: 1970957
Drug: Flunitrazepam (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam (0.25 to 2 mg/70 kg)
Study: 1970957
Drug: Lormetazepam (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lormetazepam (0.5 to 4 mg/70 kg)
Study: 1970957
Drug: Midazolam (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (1.5 to 12 mg/70 kg)
Study: 1970957
Drug: Diazepam (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (4 to 32 mg/70 kg)
Study: 1970957
Drug: Flumazenil (0.1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (0.1, 0.3 and 0.9 mg/70 kg)
Study: 7004273
Drug: Diazepam (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (0.05 mg/kg)
Study: 7004273
Drug: d-tubocurarine (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-tubocurarine (0.05 mg/kg)
Study: 23864098
Drug: Tamoxifen, 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen, 5 mg/day
Study: 21382868
Drug: E(dd)→T(dd)→CMF (dose-intensified
Approvals — FDA: no, EMA: no, PMDA: no
Description: E(dd)→T(dd)→CMF (dose-intensified chemotherapy)
Study: 21382868
Drug: EC→T (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: EC→T (standard chemotherapy)
Study: 19995249
Drug: Levobupivacaine 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 2.5 mg/ml, 15 ml every three hours for 45 hours
Study: 17853753
Drug: Premarin tablets
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Premarin tablets (control)
Study: 11486106
Drug: Lupus anticoagulant
Normalized name: Lupus anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lupus anticoagulant
Study: 11486106
Drug: Anticardiolipin/anti‐beta(2)‐glycoprotein I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticardiolipin/anti‐beta(2)‐glycoprotein I antibodies
Study: 7833657
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose (30 mCi) radioactive iodine
Study: 7833657
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (50‐250 mCi) radioactive iodine
Study: 7833657
Drug: No postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: No postoperative treatment with radioactive iodine
Study: 24294742
Drug: Sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil citrate plus Serophene (25 mg vaginally and 100-150 mg orally)
Study: 21593403
Drug: KP-1461 (400-3200
Approvals — FDA: no, EMA: no, PMDA: no
Description: KP-1461 (400-3200 mg)
Study: 21593403
Drug: KP-1461 (3200
Approvals — FDA: no, EMA: no, PMDA: no
Description: KP-1461 (3200 mg)
Study: 21593403
Drug: KP-1461 (1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: KP-1461 (1600 mg)
Study: 18284406
Drug: Sildenafil 25
Normalized name: sildenafil 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 25 mg/day at night
Study: 18284406
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no phosphodiesterase-5 inhibitors)
Study: 15125329
Drug: Combined vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined vaccine (Twinrix: HAV 720 UE/HBV 20 micrograms)
Study: 15125329
Drug: Separate vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate vaccines (Engerix B 20 micrograms/Havrix 720 UE)
Study: 15125329
Drug: Combined vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined vaccine (Twinrix)
Study: 15125329
Drug: Separate vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate vaccines (Engerix B/Havrix)
Study: 15125329
Drug: Combined vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined vaccine (Twinrix) and Separate vaccines (Engerix B/Havrix)
Study: 7641922
Drug: Fallopian sperm
Normalized name: herring sperm DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fallopian sperm perfusion with clomiphene citrate (CC)
Study: 2787664
Drug: Propofol 2.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2.8 mg kg‐1
Study: 59806
Drug: Nursing intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nursing intervention (bi-weekly visits for two months)
Study: 28414606
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline (0.9% NaCl) solution
Study: 25595580
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg intravenous azithromycin, administered 15, 30, or 60 minutes before incision, infused over 1 hour
Study: 25595580
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg intravenous azithromycin
Study: 23334506
Drug: HEC gel
Normalized name: ALCOHOL 73 L in 100 L TOPICAL GEL [Grand Valley Reagents HEC Hand Sanitizer Gel]
Approvals — FDA: no, EMA: no, PMDA: no
Description: HEC gel
Study: 23334506
Drug: No-gel
Normalized name: ALCOHOL 80 mL in 100 mL TOPICAL LIQUID [Econo-Gel EA Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-gel
Study: 11546903
Drug: Continuous intrathecal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intrathecal baclofen infusion (up to 12 months)
Study: 7810826
Drug: 1% niclosamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% niclosamide lotion applied twice a week
Study: 31829100
Drug: Enriched marine
Normalized name: marine non-gelling gelatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enriched marine oil supplement
Study: 23887151
Drug: NMDA receptor
Normalized name: NMDA receptor antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: NMDA receptor blocker ketamine during retention sleep
Study: 23887151
Drug: AMPA receptor
Normalized name: Toll-like receptor 9
DrugBank: Toll-like receptor 9 (DB15320)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMPA receptor blocker caroverine during retention sleep
Study: 23887151
Drug: NMDA receptor
Normalized name: NMDA receptor antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: NMDA receptor coagonist D-cycloserine (DCS) during retention sleep
Study: 14977793
Drug: Midazolam 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.4 mg kg(‐1)
Study: 8203789
Drug: Daflon 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daflon 500 mg (D500)
Study: 27797279
Drug: Reference brand
Normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference brand enteric‐coated capsules
Study: 27797279
Drug: Test generic
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test generic enteric‐coated tablets
Study: 23416142
Drug: α‐lipoic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: α‐lipoic acid (LA) supplementation (600 mg/day) for 28 days
Study: 17934162
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg ITM alone
Study: 17934162
Drug: 10 microg
Normalized name: Estradiol 10 microgram vaginal tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 microg ITS plus 0.4 mg ITM
Study: 15105028
Drug: Supplement containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplement containing whey protein, amino acids, creatine, and carbohydrate
Study: 11665963
Drug: Minocycline, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline, 100 mg twice per day
Study: 11665963
Drug: Hydroxychloroquine, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine, 200 mg twice per day
Study: 9440749
Drug: IVMTX 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVMTX 1,000 mg/m2 plus IVMP 1,000 mg/m2 (regimen A)
Study: 9440749
Drug: LDMTX 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDMTX 30 mg/m2 every 6 hours for six doses with IVMP 1,000 mg/m2 (regimen B)
Study: 8089345
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam at a dose of 0.5 mg/kg with 25 mg hydroxyzine pamoate suspension as a vehicle
Study: 8089345
Drug: Nasal midazolam
Normalized name: midazolam Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal midazolam at a dose of 0.2 mg/kg
Study: 8089345
Drug: Both oral
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both oral and nasal midazolam
Study: 2818919
Drug: Propofol 2.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2.25 mg kg‐1
Study: 2818919
Drug: Thiopentone 4.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopentone 4.8 mg kg‐1
Study: 2818919
Drug: Propofol 1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 1.8 mg kg‐1
Study: 2818919
Drug: Thiopentone 4.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopentone 4.7 mg kg‐1
Study: 31754133
Drug: β-blockers (atenolol)
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: β-blockers (atenolol)